Department of Radiology & Nuclear Medicine, School of Medicine, University of Jordan, Amman, Jordan.
Department of Radiology, Jordan University Hospital, Amman, Jordan.
Regen Med. 2022 May;17(5):299-312. doi: 10.2217/rme-2021-0121. Epub 2022 May 12.
This study has the primary objective of studying the effect of Wharton jelly mesenchymal stem cells (WJMSCs) in the treatment of knee osteoarthritis. As a secondary end point, we report on the efficacy of such therapy. 16 patients with advanced Kellgren stage were treated using two doses of expanded WJMSCs given 1 month apart. Patients were followed for 48 months using the Knee Injury and Osteoarthritis Outcome Score (KOOS) and 12 months using magnetic resonance imaging (MRI). Treatment was well tolerated. One patient developed moderate effusion and one superficial phlebitis. We observed functional and pain improvement at 12 and 48 months (p < 0.0001), with statistically significant improvement on MRI scans at 12 months in cartilage loss, osteophytes, bone marrow lesions, effusion and synovitis (p < 0.01), and highly significant improvement in subchondral sclerosis (p < 0.0001). WJMSCs are safe and potentially effective in producing significant improvement in KOOS and MRI scores when administered intra-articularly in knee osteoarthritis cases under ultrasound guidance.
本研究的主要目的是研究牙髓间充质干细胞（WJMSCs）在治疗膝骨关节炎中的作用。作为次要终点，我们报告了这种治疗的疗效。16 名进展期 Kellgren 患者接受了两次间隔一个月的扩张 WJMSCs 治疗。使用膝关节损伤和骨关节炎结果评分（KOOS）对患者进行了 48 个月的随访，使用磁共振成像（MRI）进行了 12 个月的随访。治疗耐受性良好。1 例患者出现中度积液，1 例患者出现浅表静脉炎。我们观察到 12 个月和 48 个月时功能和疼痛改善（p < 0.0001），12 个月时 MRI 扫描显示软骨丢失、骨赘、骨髓病变、积液和滑膜炎有统计学意义的改善（p < 0.01），软骨下硬化有显著改善（p < 0.0001）。WJMSCs 是安全的，在超声引导下关节内注射治疗膝骨关节炎时，可显著改善 KOOS 和 MRI 评分。
